SKQ-1 BROMIDE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C36H42O2P.Br
Molecular Weight	617.595
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SKQ-1 BROMIDE

Structure Search

SMILES

[Br-].CC1=C(C)C(=O)C(CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC1=O

InChI

InChIKey=WYHFWTRUGAFNKW-UHFFFAOYSA-M

InChI=1S/C36H42O2P.BrH/c1-29-30(2)36(38)31(28-35(29)37)20-12-7-5-3-4-6-8-19-27-39(32-21-13-9-14-22-32,33-23-15-10-16-24-33)34-25-17-11-18-26-34;/h9-11,13-18,21-26,28H,3-8,12,19-20,27H2,1-2H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula	C36H42O2P
Molecular Weight	537.6912
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:31:34 GMT 2023` Edited by `admin` on `Sat Dec 16 11:31:34 GMT 2023`
Record UNII	7B14500J3E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SKQ-1 BROMIDE

Code

English

SKQ1 BROMIDE

Code

English

plastoquinonyl-decyl-triphenylphosphonium bromide

Common Name

English

2,3-DIMETHYL-5-(10-(TRIPHENYL-L-5-PHOSPHANYL)DECYL)-1,4-BENZOQUINONE HYDROBROMIDE

Systematic Name

English

PHOSPHONIUM, (10-(4,5-DIMETHYL-3,6-DIOXO-1,4-CYCLOHEXADIEN-1-YL)DECYL)TRIPHENYL-, BROMIDE (1:1)

Systematic Name

English

VISOMITIN

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

846221

Created by admin on Sat Dec 16 11:31:34 GMT 2023 , Edited by admin on Sat Dec 16 11:31:34 GMT 2023

Code System Code Type Description

CAS

934826-68-3

Created by admin on Sat Dec 16 11:31:34 GMT 2023 , Edited by admin on Sat Dec 16 11:31:34 GMT 2023

PRIMARY

FDA UNII

7B14500J3E

Created by admin on Sat Dec 16 11:31:34 GMT 2023 , Edited by admin on Sat Dec 16 11:31:34 GMT 2023

PRIMARY

SMS_ID

300000040779

Created by admin on Sat Dec 16 11:31:34 GMT 2023 , Edited by admin on Sat Dec 16 11:31:34 GMT 2023

PRIMARY

PUBCHEM

16679091

Created by admin on Sat Dec 16 11:31:34 GMT 2023 , Edited by admin on Sat Dec 16 11:31:34 GMT 2023

PRIMARY

Related Record Type Details


					207SW1QYQC

SKQ-1 ION

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					207SW1QYQC

SKQ-1 ION

ACTIVE MOIETY

Comments:

Due to highly targeted delivery of SkQ1 to mitochondria and its potency as antioxidant, topical application of SkQ1-based formulations proved to be very effective in treating several eye pathologies in animal models and in humans. More than a dozen studies have been conducted and showed SkQ1 effectiveness in such critical therapeutic areas as the following: Age-related macular degeneration (AMD), Dry eye syndrome (DES), Non-infectious uveitis, Cataracts and Glaucoma.

Amount:


					207SW1QYQC

SKQ-1 ION

ACTIVE MOIETY

Comments:

In the second series, the illuminated rats were treated for two weeks with Visomitin or similar drops without SkQ1. The damaged retinas of the experimental animals were repaired much more effectively than those of the control animals. Therefore, we conclude that Visomitin SkQ1-containing eye drops have pronounced preventive and therapeutic effects on the photodamaged retina and might be recommended as a photoprotector and a pharmaceutical preparation for the treatment of AMD in combination with conventional medicines.

Amount: